Among the notable approvals in our 2Q22 drug pipeline Data Page are Alnylam's Amvuttra for hATTR amyloidosis, bmsnews's Camzyos, a first-in-class therapy for hypertrophic cardiomyopathy, and LillyPad's Olumiant, the first systemic drug for hair loss
11/30/2022 FDA PDUFA date for this engineered IgG1 anti-PD-1 mAb, which lacks the Fc gamma receptorI-radiolabeled mouse IgG1 mAb targeting B7-H3-expressing immune cells12/28/2022 FDA PDUFA date for this chimeric anti-CD20 IgG1 mAb directed towards the CD20 antigen with the glycosylation profile of LFB-R603 for enhanced ADCC10/01/2022 FDA PDUFA date for this fully human IgG2 against CTLA411/01/2022 FDA PDUFA date for this viral gene therapy consisting of AAV5 vector carrying the human factor IX...
AAV5, adeno-associated virus serotype 5; ADCC, antibody-dependent cell-mediated cytotoxicity; ADC, antibody drug conjugate; B7-H3, B7 homolog 3 protein; CD20, cluster of differentiation 20; CTLA4, cytotoxic T lymphocyte-associated antigen 4; Fc, immunoglobulin crystallizable fragment; IgA, immunoglobulin A; LFB-R603, anti-CD20 mAb; PD-1, programmed cell death protein 1; PDUFA, Prescription Drug User Fee Act.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Chief Editor, Nature Biotechnology | Nature CareersJob Title: Chief Editor\nOrganization: Nature Biotechnology\nLocation: New York, London or Berlin\n\nSpringer Nature, the publisher of Nature, is looking to recruit a Chief Editor for Nature Biotechnology. Launched in 1996, Nature Biotechnology is the flagship journal for journalistic and research content in biotechnology. The journal’s broad scope draws from the work of scientists, bioengineers and researchers in industry and academia, publishing the most impactful research in all areas of bioengineering and biotechnology. In addition to scientifically trained editors that handle the journal’s research content, the journal also employs a team of journalistic staff that publishes authoritative news and analysis covering business and scientific developments in biotechnology.\nWe are now looking for a visionary, dynamic Chief Editor, who will help further develop Nature Biotechnology as the leading publication in the field. The position will be based in one of our main offices in New York, London or Berlin.\nApplicants must have a PhD and preferably postdoctoral experience, with a strong track record in research relevant to the fields covered in the journal. Previous editorial and/or managerial experience is also required for this demanding position.\nThe successful applicant will lead an editorial and journalistic team and work closely with them on all aspects of the editorial process, including research manuscript peer review as well as writing, editing and commissioning Editorials, News, Features, Reviews, News & Views and other content. A key aspect of the job is liaising with the scientific community through laboratory visits and international conferences — willingness to travel is essential.\nThis leadership role calls for a keen interest in the practice and communication of science and authoritative command of the main trends in research and business related to biotechnology. The successful candidate will be dynamic and have excellent interpersonal skills. Broa
Read more »
Patents benefit patients and patent reform would spur diagnostic and therapeutic development - Nature BiotechnologyPatients need the patent system to spur the investment necessary for the continued development of life-saving diagnostics and therapies.
Read more »
HER3-addicted tumors: how biotechs are closing in - Nature BiotechnologyThe elusive HER3, known to drive aggressive cancers, may finally be toppled by once-abandoned antibody drugs.
Read more »
How David Lynch Approaches the Nature of Evil in ‘Twin Peaks: Fire Walk With Me’30 years later, a look back on how David Lynch's TwinPeaksFireWalkWithMe shows the ways that evil exploits good.
Read more »
Tropical cyclone-blackout-heatwave compound hazard resilience in a changing climate - Nature CommunicationsThe study found that long-duration heatwaves are much more likely to follow power-damaging tropical cyclones in the future RCP8.5 climate, with the impact of longer-than-5-day tropical cyclone-blackout-heatwave compound hazard increasing by a factor of 23 over the 21st century.
Read more »
The Inflation Reduction Act Adds Agricultural Nature-Based Solutions To The Climate ToolkitThis article describes how nature-based agricultural funding may incentivize farmers to embrace climate-friendly practices.
Read more »